宫颈癌诊治热点与进展

doi:10.3969/j.issn.1006-5725.2024.17.001

Abstract

Abstract:

Cervical cancer is a prevalent gynecological malignancy worldwide， and despite established measures for prevention， detection， and treatment at different stages， limited success has been achieved in effectively reducing its incidence. While treatments such as surgery for early-stage patients， adjuvant chemoradiotherapy based on postoperative pathology assessment of high-risk factors and intermediate risk factors， combined radiochemotherapy for patients at all stages， and systemic treatment for advanced cervical cancer have demonstrated effectiveness in numerous cases. Recent advancements in surgical pathology staging， selection of surgical approaches， options available for early-stage cases， utilization of neoadjuvant chemotherapy， novel approaches to radiotherapy administration， as well as clinical trials investigating new drugs targeting recurrent and metastatic cervical cancer have contributed to more precise and individualized treatment strategies while providing a wider range of choices. Therefore， this manuscript comprehensively discusses important developments concerning the diagnosis and treatment of cervical cancer with the aim of offering an improved reference for clinical practice.

Key words: cervical cancer, diagnosis, treatment, gynecological tumor, radiochemotherapy

CLC Number:

R737.3

Qingwei ZHANG,Rutie. YIN. Hotspots and advances on diagnosis and treatment for cervical cancer[J]. The Journal of Practical Medicine, 2024, 40(17): 2357-2362.

References 46

1	SINGH D， VIGNAT J， LORENZONI V， et al. Global estimates of incidence and mortality of cervical cancer in 2020： a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative［J］. Lancet Glob Health， 2023，11（2）： e197-e206. doi:10.1016/s2214-109x(22)00501-0 doi: 10.1016/s2214-109x(22)00501-0
2	SALEH M， VIRARKAR M， JAVADI S， et al. Cervical Cancer： 2018 Revised International Federation of Gynecology and Obstetrics Staging System and the Role of Imaging［J］. AJR Am J Roentgenol， 2020，214（5）： 1182-1195. doi:10.2214/ajr.19.21819 doi: 10.2214/ajr.19.21819
3	MOHAMUD A， HOGDALL C， SCHNACK T. Prognostic value of the 2018 FIGO staging system for cervical cancer［J］. Gynecol Oncol， 2022，165（3）： 506-513. doi:10.1016/j.ygyno.2022.02.017 doi: 10.1016/j.ygyno.2022.02.017
4	ZENG J， QU P， HU Y， et al. Clinicopathological risk factors in the light of the revised 2018 International Federation of Gynecology and Obstetrics staging system for early cervical cancer with staging IB： A single center retrospective study［J］. Medicine （Baltimore）， 2020，99（16）： 1-6. doi:10.1097/md.0000000000019714 doi: 10.1097/md.0000000000019714
5	周琦，邹冬玲，向阳，等. 子宫颈癌手术分期中国专家共识（2023年版）［J］. 中国实用妇科与产科杂志， 2023，39（10）： 996-1002.
6	鲁琦，张震宇. 国际妇产科联盟2018年版子宫颈癌分期标准的解读［J］. 中华妇产科杂志，2019，54（10）：718-720. doi:10.3760/cma.j.issn.0529-567x.2019.10.014 doi: 10.3760/cma.j.issn.0529-567x.2019.10.014
7	WRIGHT J D， MATSUO K， HUANG Y， et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines［J］. Obstet Gynecol， 2019，134（1）： 49-57. doi:10.1097/aog.0000000000003311 doi: 10.1097/aog.0000000000003311
8	FANG C， ZHANG P， YU A， et al. Different prognosis of stage ⅢB cervical cancer patients with lower third of vaginal invasion and those without［J］. Gynecol Oncol， 2021，162（1）： 50-55. doi:10.1016/j.ygyno.2021.04.005 doi: 10.1016/j.ygyno.2021.04.005
9	RAMIREZ P T， FRUMOVITZ M， PAREJA R， et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer［J］. N Engl J Med， 2018，379（20）： 1895-1904. doi:10.1056/nejmoa1806395 doi: 10.1056/nejmoa1806395
10	AHN J H， YUN J， YUN C Y， et al. Is there a relationship between surgical proficiency and oncologic outcome of minimally invasive radical hysterectomy for early-stage cervical cancer？［J］. Int J Med Sci， 2023，20（4）： 551-556.
11	LV X， DING B， XU J， et al. Effect of modified radical laparoscopic hysterectomy versus open radical hysterectomy on short-term clinical outcomes in early-stage cervical cancer： a single-center， prospective， randomized controlled trial［J］. World J Surg Oncol， 2023，21（1）： 167. doi:10.1186/s12957-023-03044-3 doi: 10.1186/s12957-023-03044-3
12	COURCIER H， AZAIS H， BELGHITI J， et al. Minimally invasive surgery for early-stage cervical cancer： Rediscovering the Schautheim robot-assisted procedure［J］. J Gynecol Obstet Hum Reprod， 2021，50（2）： 1-12. doi:10.1016/j.jogoh.2020.101980 doi: 10.1016/j.jogoh.2020.101980
13	LI R Z， SUN L F， LI R， et al. Survival after minimally invasive radical hysterectomy without using uterine manipulator for early-stage cervical cancer： A systematic review and meta-analysis［J］. BJOG， 2023，130（2）： 176-183. doi:10.1111/1471-0528.17339 doi: 10.1111/1471-0528.17339
14	高京海，孟元光，陈必良，等. 单孔机器人手术治疗早期宫颈恶性肿瘤中国专家共识（2023版）：附视频［J］. 机器人外科学杂志（中英文）， 2023，4（6）： 578-592.
15	范江涛，刘淑娟，庞晓燕，等. 子宫颈癌腹腔镜技术诊治指南（2023年版）［J］. 中国实用妇科与产科杂志， 2023，39（3）： 296-302.
16	QUERLEU D， HUDRY D， NARDUCCI F， et al. Radical Hysterectomy After the LACC Trial： Back to Radical Vaginal Surgery［J］. Curr Treat Options Oncol， 2022， 23（2）： 227-239. doi:10.1007/s11864-022-00937-5 doi: 10.1007/s11864-022-00937-5
17	周晖，刘昀昀，罗铭，等. 《2023 NCCN子宫颈癌临床实践指南（第1版）》解读［J］. 中国实用妇科与产科杂志， 2023，39（2）： 189-196.
18	SCHMELER K M， PAREJA R， LOPEZ B A， et al. ConCerv： a prospective trial of conservative surgery for low-risk early-stage cervical cancer［J］. Int J Gynecol Cancer， 2021，31（10）： 1317-1325. doi:10.1136/ijgc-2021-003008 doi: 10.1136/ijgc-2021-003008
19	MARIE PLANTE J S K S， AMANDINE MAULARD C D K W， KARL TAMUSSINO S K F G， et al. An international randomized phase Ⅲ trial comparing radical hysterectomy and pelvic node dissection （RH） vs simple hysterectomy and pelvic node dissection （SH） in patients with low-risk early-stage cervical cancer （LRESCC）［J］. J Clin Oncol， 2023，41（S1）： A5511. doi:10.1200/jco.2023.41.17_suppl.lba5511 doi: 10.1200/jco.2023.41.17_suppl.lba5511
20	CARNEIRO V， BATISTA T P， ANDRADE M R， et al. Proof-of-concept randomized phase Ⅱ non-inferiority trial of simple versus type B2 hysterectomy in early-stage cervical cancer </=2 cm （LESSER）［J］. Int J Gynecol Cancer， 2023，33（4）： 498-503. doi:10.1136/ijgc-2022-004092 doi: 10.1136/ijgc-2022-004092
21	张剑峰，张旭垠，丁岩，等. 子宫颈癌手术治疗质量控制与质量评价标准中国专家共识（2023年版）［J］. 中国实用妇科与产科杂志， 2023，39（7）： 712-724.
22	CIBULA D， RASPOLLINI M R， PLANCHAMP F， et al. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023［J］. Int J Gynecol Cancer， 2023，33（5）： 649-666. doi:10.1136/ijgc-2023-004429 doi: 10.1136/ijgc-2023-004429
23	SCHUBERT M， BAUERSCHLAG D O， MUALLEM M Z， et al. Challenges in the Diagnosis and Individualized Treatment of Cervical Cancer［J］. Medicina （Kaunas）， 2023， 59（5）： 1-19. doi:10.3390/medicina59050925 doi: 10.3390/medicina59050925
24	中国医师协会妇产科医师分会人工智能专业组. 子宫颈癌手术治疗质量控制标准中国专家共识之QM-C1型广泛性子宫切除篇［J］. 中国实用妇科与产科杂志， 2022， 38（4）： 434-442.
25	BIZZARRI N， QUERLEU D， DOSTALEK L， et al. Survival associated with extent of radical hysterectomy in early-stage cervical cancer： a subanalysis of the Surveillance in Cervical CANcer （SCCAN） collaborative study［J］. Am J Obstet Gynecol， 2023，229（4）： 421-428. doi:10.1016/j.ajog.2023.06.030 doi: 10.1016/j.ajog.2023.06.030
26	王刚. 宫颈癌保留生育功能手术的决策与技巧［J］. 中国计划生育和妇产科， 2022，14（8）：9-13. doi:10.3969/j.issn.1674-4020.2022.08.03 doi: 10.3969/j.issn.1674-4020.2022.08.03
27	SLAMA J， RUNNEBAUM I B， SCAMBIA G， et al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment： The FERTIlity Sparing Surgery retrospective multicenter study［J］. Am J Obstet Gynecol， 2023，228（4）： 441-443. doi:10.1016/j.ajog.2022.11.1295 doi: 10.1016/j.ajog.2022.11.1295
28	GUPTA S， MAHESHWARI A， PARAB P， et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2， ⅡA， or ⅡB Squamous Cervical Cancer： A Randomized Controlled Trial［J］. J Clin Oncol， 2018，36（16）： 1548-1555. doi:10.1200/jco.2017.75.9985 doi: 10.1200/jco.2017.75.9985
29	KENTER G G， GREGGI S， VERGOTE I， et al. Randomized Phase Ⅲ Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-ⅡB Cervical Cancer： EORTC-55994［J］. J Clin Oncol， 2023，41（32）： 5035-5043. doi:10.1200/jco.22.02852 doi: 10.1200/jco.22.02852
30	MCCORMACK M， RINCÓN D G， EMINOWICZ G， et al. A randomised phase Ⅲ trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer： The GCIG INTERLACE trial［J］. Ann Oncol， 2023，34（S2）： S1276. doi:10.1016/j.annonc.2023.10.028 doi: 10.1016/j.annonc.2023.10.028
31	POTTER R， TANDERUP K， SCHMID M P， et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer （EMBRACE-I）： a multicentre prospective cohort study［J］. Lancet Oncol， 2021，22（4）： 538-547.
32	MAYADEV J S， KE G， MAHANTSHETTY U， et al. Global challenges of radiotherapy for the treatment of locally advanced cervical cancer［J］. Int J Gynecol Cancer， 2022，32（3）： 436-445. doi:10.1136/ijgc-2021-003001 doi: 10.1136/ijgc-2021-003001
33	COBUSSEN A， PETRIC P， WULFF C N， et al. Clinical outcomes using a 3D printed tandem-needle-template and the EMBRACE-Ⅱ planning aims for image guided adaptive brachytherapy in locally advanced cervical cancer［J］. Acta Oncol， 2023，62（11）： 1470-1478. doi:10.1080/0284186x.2023.2246642 doi: 10.1080/0284186x.2023.2246642
34	SCHEFTER T， WINTER K， KWON J S， et al. RTOG 0417： Efficacy of Bevacizumab in Combination with Definitive Radiation Therapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma［J］. Int J Radiat Oncol Biol Phys， 2014，88（1）： 101-105. doi:10.1016/j.ijrobp.2013.10.022 doi: 10.1016/j.ijrobp.2013.10.022
35	LORUSSO D， XIANG Y， HASEGAWA K， et al. LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer： A randomized， double-blind， phase Ⅲ ENGOT-cx11/GOG-3047/KEYNOTE-A18 study［J］. Ann Oncol， 2023，34（s2）： S1279-S1280. doi:10.1016/j.annonc.2023.10.032 doi: 10.1016/j.annonc.2023.10.032
36	ZHONG L， LI K， SONG L， et al. The effect of consolidation chemotherapy after concurrent chemoradiation on the prognosis of locally advanced cervical cancer： a systematic review and meta-analysis［J］. J Obstet Gynaecol， 2022，42（5）： 830-837. doi:10.1080/01443615.2021.2012437 doi: 10.1080/01443615.2021.2012437
37	MILESHKIN L R， MOORE K N， BARNES E H， et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone （OUTBACK）： an international， open-label， randomised， phase 3 trial［J］. Lancet Oncol， 2023，24（5）： 468-482. doi:10.1016/s1470-2045(23)00147-x doi: 10.1016/s1470-2045(23)00147-x
38	MONK B J， COLOMBO N， TEWARI K S， et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent， Recurrent， or Metastatic Cervical Cancer： Final Overall Survival Results of KEYNOTE-826［J］. J Clin Oncol， 2023，41（36）： 5505-5511. doi:10.1200/jco.23.00914 doi: 10.1200/jco.23.00914
39	TEWARI K S， COLOMBO N， MONK B J， et al. Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent， Recurrent， or Metastatic Cervical Cancer： Subgroup Analyses from the KEYNOTE-826 Randomized Clinical Trial［J］. JAMA Oncol，2024，10（2）：185-192. doi:10.1001/jamaoncol.2023.5410 doi: 10.1001/jamaoncol.2023.5410
40	ABU-RUSTUM N R， YASHAR C M， AREND R， et al. NCCN Guidelines（R） Insights： Cervical Cancer， Version 1.2024［J］. J Natl Compr Canc Netw， 2023，21（12）： 1224-1233.
41	O'MALLEY D M， NEFFA M， MONK B J， et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer： An Open-Label Phase Ⅱ Study［J］. J Clin Oncol， 2022，40（7）： 762-771. doi:10.1200/jco.21.02067 doi: 10.1200/jco.21.02067
42	GAO X， XU N， LI Z， et al. Safety and antitumour activity of cadonilimab， an anti-PD-1/CTLA-4 bispecific antibody， for patients with advanced solid tumours （COMPASSION-03）： a multicentre， open-label， phase 1b/2 trial［J］. Lancet Oncol， 2023，24（10）： 1134-1146. doi:10.1016/s1470-2045(23)00411-4 doi: 10.1016/s1470-2045(23)00411-4
43	张清伟，付秀虹，吕净上. Tisotumab vedotin治疗宫颈癌的研究进展［J］. 实用医学杂志， 2022，38（15）：1860-1864. doi:10.3969/j.issn.1006-5725.2022.15.003 doi: 10.3969/j.issn.1006-5725.2022.15.003
44	VERGOTE I B， GONZALEZ MARTIN A， FUJIWARA K，et al. InnovaTV 301/ENGOT-cx12/GOG-3057： a global，randomized， open-label， phase Ⅲ study of tisotumab vedotinvs investigator′s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer［J］. Ann Oncol， 2023， 34（s2）： S1276-S1277. doi:10.1016/j.annonc.2023.10.029 doi: 10.1016/j.annonc.2023.10.029
45	MERIC-BERNSTAM F， MAKKER V， OAKNIN A， et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors： Primary Results From the DESTINY-PanTumor02 Phase Ⅱ Trial［J］. J Clin Oncol， 2024，42（1）： 47-58. doi:10.1200/jco.23.02005 doi: 10.1200/jco.23.02005
46	谢玲玲，林仲秋. 《2024 NCCN子宫肿瘤临床实践指南（第1版）》解读［J］. 中国实用妇科与产科杂志， 2023，39（11）： 1122-1127.

[1]	Qiaofang HUANG,Xingxiao HUANG,Junyi LIN,Lian DUAN,Zhentai PANG,Shaojuan WU,Caimei ZOU,Shichao XU. Effect of physician⁃nurse⁃social worker linkage rehabilitation model on psychological status in patients receiving methadone maintenance treatment [J]. The Journal of Practical Medicine, 2024, 40(9): 1238-1243.
[2]	Tianyue CUI,Liquan OUYANG,Shengchu. ZHANG. Clinical efficacy of simple surgery and surgery combined with glucocorticoids in the treatment of mass type granulomatous mastitis [J]. The Journal of Practical Medicine, 2024, 40(9): 1268-1274.
[3]	Min ZHAO,Ping NI,Huiying ZHAI,Xiaoke JIN,Yuqiong. YANG. Analysis of the expression of lymphoid enhancer binding factor 1 in B cell chronic lymphoproliferative disorders [J]. The Journal of Practical Medicine, 2024, 40(7): 984-988.
[4]	Shuangyan LI,Bin ZHANG. Research status and challenges of insomnia disorder [J]. The Journal of Practical Medicine, 2024, 40(6): 731-737.
[5]	Yuxin CHENG,Liang LIU,Shiyu DONG,Shengchao LI,Meng ZHANG. Research advances in exosomal proteins， mRNA and non⁃coding RNA regulation of Hepatocellular Carcinoma [J]. The Journal of Practical Medicine, 2024, 40(6): 748-755.
[6]	Pengshuai SUN,Feng ZHU,Lihong ZHENG,Haiqiang WANG. Research progress in the treatment of AMPK regulating lipid accumulation in the treatment of nonalcoholic fatty liver disease [J]. The Journal of Practical Medicine, 2024, 40(6): 862-866.
[7]	Juan TANG,Yi LI,Liqiong ZHAI,Shaowen LIU,Yong SHEN,Shuo CONG,Yongmei. LIU. The diagnostic value of miR⁃571 levels in blood from the peripherals in liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(5): 653-657.
[8]	Jing HU,Xu WANG,Xiaoqin GONG,Rui LING,Tao YOU,Chunhua DAI,Ye TIAN,Fei. CHEN. Analysis of dosimetric parameters of acute radiation enteritis in cervical cancer patients treated with concurrent chemoradiotherapy [J]. The Journal of Practical Medicine, 2024, 40(5): 672-676.
[9]	Weifeng LIU,Zheng DAI,Yibin ZHOU,Kaiwen FENG,Kai WEI,Gule SUN,Dongrong YANG,Jin. ZHU. The value of urine protein kinase Y⁃linked gene promoter site methylation in early diagnosis of prostate cancer [J]. The Journal of Practical Medicine, 2024, 40(5): 688-694.
[10]	Rui XU,Xingbing. HUANG. Progress of non-pharmacological treatments for treatment-resistant depression [J]. The Journal of Practical Medicine, 2024, 40(4): 439-446.
[11]	Yigang TAN,Haobin KUANG,Hongmei FU,Chunyan LI,Xiaobing ZHAO,Lijing XUE. Analysis of clinical characteristics of 33 cases of tuberculosis complicated by tumor necrosis factor⁃α inhibitor in autoimmune diseases [J]. The Journal of Practical Medicine, 2024, 40(3): 378-383.
[12]	Haijing CHEN,Yaying YANG,Wei ZHAO,Jihong HU,Li WU,Linglin ZHENG,Yan WU,Qingqing LI. Contrast⁃enhanced CT and MRI in differentiating squamous cell carcinoma of the nasal cavity and sinuses from lymphoma [J]. The Journal of Practical Medicine, 2024, 40(3): 394-399.
[13]	Chao SHENG,Zhijian. WANG. Early identification， standardized diagnosis and treatment of placenta accreta spectrum disorders [J]. The Journal of Practical Medicine, 2024, 40(21): 2965-2970.
[14]	Shijun LUO,Lizi ZHANG,Dunjin. CHEN. Diagnosis， prevention and treatment of placenta accreta spectrum with non⁃traumatic factors [J]. The Journal of Practical Medicine, 2024, 40(21): 2971-2975.
[15]	Yu LIU,Li WANG,Bingfang CHEN,Kewen SUN,Yin. ZHANG. The efficacy of pancreatic fluid molecular biomarkers for diagnosis of pancreatic cancer [J]. The Journal of Practical Medicine, 2024, 40(21): 3101-3106.

Hotspots and advances on diagnosis and treatment for cervical cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 46

Related Articles 15

Recommended Articles

Metrics

Comments